Articles related to RHEUMATOID ARTHRITIS (RA)

A single-institution case series of 13 biopsy-proven hydroxychloroquine cardiomyopathy patients documented variable outcomes after drug cessation, ranging from full functional recovery to progression requiring advanced heart failure therapies.

The American Academy of Ophthalmology updated hydroxychloroquine retinopathy screening recommendations, emphasizing dose limits, OCT and FAF as primary screening modalities, and risk stratification by renal status and concurrent tamoxifen use.

Early treatment phases may transiently promote immune activation, whereas sustained therapy, by reducing BMI and lowering systemic inflammation, may mitigate this effect.

After implantation during a minimally invasive outpatient procedure, the SetPoint device is programmed to automatically administer therapy on a predetermined schedule for up to 10 years, simplifying care for people living with RA.

Understanding the role of antidrug antibodies in RA treatment can significantly impact patient management. Stay updated on how these antibodies correlate with bDMARD effectiveness to optimize your treatment plans.

This pooled analysis provides robust evidence that low-dose glucocorticoids in RA treatment result in modest weight gain but do not elevate blood pressure. Consider these findings in your risk-benefit discussions with patients.